Diabetes is a chronic disease associated with increased morbidity and mortality (1), mainly from cardiovascular disease (2–6). Treatment of diabetes includes normalizing hyperglycemia to attain glycemic targets and treatment of cardiovascular risk factors such as hypertension and dyslipidemia. This multifactorial intervention strategy has been shown to decrease cardiovascular and all-cause mortality among patients with type 2 diabetes (7). Nevertheless, mortality in diabetes remains elevated (2,5). A number of epidemiological studies have quantified the risk of death among patients with diabetes and assessed the causes of death (2–6), with highly varying results (Table 1). The South Tees Diabetes Mortality Study (2) found an over threefold increase in all-cause mortality, mainly attributed to increased cardiovascular deaths, but found no increased risk of cancer mortality. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) (3) of over 10,000 individuals reported a little over twofold increase in the risk of all-cause mortality, with the majority due to cardiovascular causes. The Emerging Risk Factors Collaboration (ERFC) study (6), involving over 800,000 individuals, reported a little under twofold increase in the risk of all-cause mortality associated with diabetes. It also found that diabetes was associated with an increased risk of death from cancer (hazard ratio [HR] 1.25 [95% CI 1.19–1.31]), from vascular disease (HR 2.32 [95% CI 2.11–2.56]), and from nonvascular and noncancer etiologies (HR 1.73 [95% CI 1.62–1.85]).
Testosterone and other AAS, which have a schedule III classification by the Controlled Substances Act, may be abused by adults and adolescents, including athletes and body builders.
“Abuse of testosterone, usually at doses higher than those typically prescribed and usually in conjunction with other AAS, is associated with serious safety risks affecting the heart, brain, liver, mental health, and endocrine system,” the FDA notes.
Reported serious adverse outcomes include myocardial infarction, heart failure, stroke, depression, hostility, aggression, liver toxicity, and male infertility. People abusing high doses of testosterone have also reported withdrawal symptoms, such as depression, fatigue, irritability, loss of appetite, decreased libido, and insomnia, the agency says.
It is interesting you no longer see those Low-T commercials on television any more. Really? Just another clever marketing campaign to create a disease that doesn’t exist along with a convenient drug based solution. What side effects?
Read this book. Now.
The top executive at Genworth Financial Inc. assured analysts and investors Monday that the proposed sale to a China-based investment firm was “the best option” to preserve and create value for shareholders.
Genworth, a major seller of home mortgage insurance and long-term care insurance, announced Sunday evening that its board agreed for the Henrico County-based company to be bought for about $2.7 billion by Beijing-based China Oceanwide Holdings Group, a privately held international financial company that has been expanding its holdings in the U.S.
MetLife decided earlier this year to part with most of its U.S. life-insurance business. Now it is cutting ties with Snoopy.
Could the Gecko be next???
The Oklahoman link is to their online comics section for October 21, 2016.
Scroll to the bottom of the page for the Peanuts strip.